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Abstract
Oral pre-exposure prophylaxis (PrEP) significantly reduces human immunodeficiency virus (HIV) acquisition risk. However, data on
predictors of PrEP uptake in sub-Saharan Africa are limited. We assessed predictors of PrEP uptake among HIV-uninfected high risk
individuals enrolled in a HIV vaccine preparedness study in Masaka, Uganda.
Between July 2018 and October 2020, we recruited adults (18–40years) from sex work hotspots along the trans-African highway
and Lake Victoria fishing communities. We collected baseline data on socio-demographics and PrEP awareness, and provided HIV
counselling and testing, information on PrEP, and PrEP referrals at quarterly visits. Urine pregnancy tests (women) and data collection
on sexual risk behaviour and PrEP uptake were performed every 6months. We analysed PrEP uptake among participants who had
completed 6months of follow-up.
Of the 588 cohort participants, 362 (62%) were included in this analysis. Of these, 176 (49%) were female, 181 (50%) were aged
24years, 104 (29%) worked in sex work hotspots, 74 (20%) were fisher folk. Only 75 (21%) participants initiated PrEP. Predictors of
PrEP uptake included having≥6 sex partners (adjusted odds ratio [aOR]=2.29; 95% confidence interval [CI] 1.26–4.17), engaging in
transactional sex (aOR=2.23; 95% CI 0.95–5.20), and residence in a nonfishing community (aOR=2.40; 95% CI 1.14–5.08). The
commonest reasons for not starting PrEP were pill burden (38%) and needing more time to decide (27%).
PrEP uptake was low and associated with HIV risk indicators in this cohort. Interventions are needed to improve access to PrEP
especially in fishing communities.
Abbreviations: AIDS = acquired immunodeficiency syndrome, aOR = adjusted odds ratio, ART = antiretroviral therapy, CI =
confidence interval, HCT = HIV counselling and testing, HIV = human immunodeficiency virus, MSM =men who have sex with men,
OR = odds ratio, PrEP = pre-exposure prophylaxis, SSA = sub-Saharan Africa.
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Despite various human immunodeficiency virus (HIV) prevention
interventions, HIV remains a major global public health problem.
In 2018, 1.7 million new infections were reported globally, with
66% of these infections occurring in sub-Saharan Africa (SSA).[1]
Majority of these infections were among key populations (menwho
have sexwithmen, female sex workers, injecting drug users, others)
and their sexual partners. The slow decline in new infections has
been termed a prevention crisis by Joint UnitedNations Programme
onHIV/acquired immunodeficiency syndrome (AIDS).[2] It has been
suggested that in the absence of a cure and/or vaccine against HIV,
acceptance of prevention interventions like pre-exposure prophy-
laxis (PrEP) needs to be increased rapidly.[1,3]
PrEP is widely considered as an effective prevention interven-
tion for populations at high risk of acquiring HIV. Several trials
demonstrated the efficacy of tenofovir disoproxil fumarate and
emtricitabine (Truvada) in reducing the risk of HIV transmis-
sion.[4] Based on this evidence, the US Food and Drug
Administration approved the use of Truvada as PrEP in
2012.[5] The World Health Organization also recommended
the adoption of PrEP as one of the strategies to combat new HIV
infections among key populations.[6] Countries in the developed
world embraced PrEP earlier[7] and roll out is currently ongoing
in other countries including in SSA.[3,8]
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In 2016, a declaration was made by the United Nations General
Assembly to provide oral PrEP to 3million people at risk of HIV
infection by 2020, but by the end of 2017, only 350,000 people
had ever taken PrEP with two-thirds of the users in the United
States of America.[9] Expansion of PrEP provision in SSA will
particularly require effectively engaging most at-risk populations
who account for 25% of new HIV infections.[10] However, data
on barriers and facilitators of PrEP uptake in this population are
limited. The aim of this study was to assess predictors of PrEP
uptake among adults at high risk of HIV infection who were
enrolled in an HIV vaccine preparedness study in Masaka,
Uganda.2. Materials and methods
2.1. Study design and participants
This analysis used data from anHIV vaccine preparedness cohort
study “The PrEPVacc registration cohort”. The aim of the
PrEPVacc registration cohort study was to prepare a population
of HIV-negative individuals who are at risk of acquiring HIV for
possible participation in the PrEPVacc HIV vaccine efficacy
trial.[11] The study was initiated in July 2018 and is taking
place at 5 clinical research sites in South Africa, Mozambique,
Tanzania, and Uganda.
In Uganda, the study was conducted at the Medical Research
Council/Uganda Virus Research Institute and London School of
Hygiene and Tropical Medicine Uganda Research Unit’s clinical
research site in Masaka city, Masaka district. Study participants
were recruited from sex work hotspots along the trans-African
highway and fishing communities along the shores of Lake
Victoria within a radius of approximately 80km from Masaka
city. To be eligible for the study, individuals had to be 18 to 40
years old, HIV-negative, willing to provide locator information
and available for follow-up, and be at risk of HIV infection as
defined by any of the following: suspected/confirmed sexually
transmitted infection or unprotected sex with ≥2 partners or
unprotected sex with a new partner in the past 3months or
unprotected sex in exchange for money/goods in the past month.2.2. PrEP services
The PrEP programme in greater Masaka region (Masaka district
and 9 neighbouring districts) is implemented at 10 health facilities
spread across the region under the stewardship of the regional
implementing partner, Rakai Health Sciences Program. The
programme is supported by the U.S. President’s Emergency Plan
for AIDS Relief through the US Centers for Disease Control and
Prevention – Uganda.[12] The health facilities are located within a
range of 1km (eg, The AIDS Support Organisation – Masaka
clinic) to 74km (eg, Lyantonde hospital) of the clinical research
site in Masaka.
PrEP is provided according to the national guidelines to
individuals who are considered to be at substantial risk of HIV
acquisition as per the following criteria: unprotected vaginal sex
with more than 1 partner of unknown HIV status in the past 6
months; anal sex in the past 6months; transactional sex in the last
6 months; use or abuse of drugs especially injectable drugs in the
last 6 months; more than 1 episode of a sexually transmitted
infections within the last 12 months; partner of a discordant
couple, especially if the HIV-positive partner is not on2
antiretroviral therapy (ART) or has been on ART for less than
6 months or not virally suppressed; recurrent (>3 times per year)
postexposure prophylaxis; belonging to a key population and
being unable or unwilling to achieve consistent use of
condoms.[13] All PrEPVacc registration cohort participants were
eligible for oral PrEP.2.3. Sample size considerations
Assuming a PrEP uptake of 30% as reported in previous
studies,[14,15] it was estimated that a minimum of 282
participants would provide more than 80% power to identify
predictors that increase the likelihood of starting PrEP by an
odds ratio (OR) ≥2. A larger sample size would be needed if
PrEP uptake were to be lower than 30%. For example, 344
participants would be needed if PrEP uptake were 20%.2.4. Procedures
Prospective study participants were identified through HIV
counselling and testing (HCT) outreaches in the study communi-
ties. Individuals who tested HIV-negative were provided brief
information about the study and those who expressed interest
invited to the study clinic for screening and possible enrollment.
Screening and enrollment were conducted at the same visit.
Screening procedures consisted of provision of detailed study
information, obtaining written informed consent, repeat HCT,
urine pregnancy testing (women), eligibility assessment, and
enrollment for those eligible. Enrollment procedures consisted of
collection of locator, socio-demographics, and HIV risk
behaviour data. An experienced study counsellor provided
information on oral PrEP including its benefits and possible side
effects, PrEP adherence counselling, and for individuals whowere
willing to initiate PrEP, a written referral to a PrEP provider.
At quarterly visits, participants received HCT and information
and counselling on and referrals for PrEP as appropriate. Every
6months, participants had a urine pregnancy test done (women)
and completed questionnaires on HIV risk behaviour and PrEP
uptake.2.5. Laboratory methods
Blood was obtained by venepuncture for testing using HIV rapid
test kits: Alere Determine HIV-1/HIV-2 (Alere Medical Co Ltd,
357 Matsuhidai Matsudo-shi, Chiba-ken 270- 2214, Japan) for
screening, Stat-Pak HIV 1/2 (Chembio Diagnostic systems, New
York, NY11763) for confirmation of positive results, and
Standard Diagnostics Bio line (Standard Diagnostics, Kyonggi-
do, South Korea) as tie-breaker. ß-Human chorionic gonadotro-
pin reagent strips (QuickVue hCG Combo, Quidel Corporation,
San Diego, CA92121) were used to perform urine pregnancy
testing.2.6. Statistical analysis
Data management and analysis were conducted in OpenClinica
(Community Edition) and Stata version 15.0 (College Station,
TX), respectively. The analysis was restricted to those partic-
ipants who had completed 6months of follow-up. Participant
characteristics were summarised using frequencies and percen-
tages for categorical variables and means (standard deviation)
and/or medians (interquartile ranges) for continuous variables.
Table 1
Baseline socio-demographic characteristics of 362 at-risk indivi-
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PrEP uptake. Predictors that had a P-value .2 at bivariate
analysis were included in the multivariable analysis. Variables
were retained in the multivariable model if their P-value was .1
using backward selection (Wald). Only age and gender were
included a priori. OR and 95% confidence intervals (CI) were
reported at both univariate and multivariable analysis.Male 186 (51)
Female 176 (49)
Mean age (SD) 26 (6.0)
Age
24 181 (50)
25– to 34 142 (39)
≥35 39 (11)
Education
Primary school and below 241 (67)






The PrEPVacc registration cohort study was approved by the
Uganda Virus Research Institute Research Ethics Committee
(GC/127/18/03/637), the Uganda National Council for Science
and Technology (HS2392). All participants provided written
informed consent before undergoing study procedures. Individu-
als who tested HIV-positive at any of the study visits were
provided post-test counselling and referred for HIV care.
Additionally, pregnant HIV-positive female participants were





Sex worker 69 (19)
Subsistence fisheries worker 74 (20)
Salon/lodge/bar worker, market/street vendor 104 (29)
Other† 141 (39)
Residence
Fishing village 140 (39)
Nonfishing village 222 (61)
Source of income
Sex work 69 (19)
Other‡ 293 (81)
SD= standard deviation.3. Results
ByOctober 2020, a total of 862 individuals had been screened for
eligibility of whom 588 (68%) were enrolled in the PrEPVacc
registration cohort. The commonest reasons for ineligibility were
being at low risk for HIV infection (n=265, 97%) and HIV
infection (n=5, 2%). Of those enrolled, 362 (62%) had
completed the month-6 follow-up visit. The mean age of
participants in this group was 26years (standard deviation=
6.0). Most were male (51%), single or divorced/separated/
widowed (59%), and only had primary school education or less
(67%) (Table 1).Bold indicate the level of significance of the P-value <0.05
∗
Multiple options allowed.
† Professional/technical worker, sales/service worker, office clerk, student, etc.
‡ Formal/informal employment, family, spouse, etc.3.1. Oral PrEP uptake and associated factors
At the month 6 visit, only 75 (21%) participants reported having
started oral PrEP at 5 health facilities. Reasons for not starting
oral PrEP included: pill burden (38%), needing more time to
decide (27%), unavailability of PrEP in participant’s area of
residence (7%), fear of stigmatisation (6%), partner refusal/
needing more time to discuss with partners (6%), preference for
condoms (5%), plans to change behaviour (4%), fear of side
effects (1%), and being currently pregnant (1%). None of the
participants who made it to the referral site was found to be
ineligible for PrEP.
At bivariate analysis, being female (OR=2.56, 95% CI 1.5–
4.36), residence in a nonfishing village (OR=2.34, 95%CI 1.31–
4.18), occupation [sex worker (OR=3.89, 95% CI 2.20–6.90);
other (OR=0.46, 95% CI 0.26–0.81)], transactional sex in the
past month (OR=4.14, 95% CI 1.91–8.98), condom use at last
sex act (OR=2.24 95% CI 1.30–3.86), having a sexual partner
who is older by 10years (OR=2.33 95% CI 1.38–3.94), ≥6
partners (OR=3.87 95% CI 2.28–6.56) and awareness of PrEP
at baseline (OR=1.83, 95% CI 1.10–3.06) were associated with
uptake of PrEP. At multivariable analysis, residence in a
nonfishing village (adjusted odds rations [aOR]=2.40, 95%
CI 1.14–5.08), occupation [salon/lodge/bar worker/market or
street vendor (aOR) aOR=0.40, 95% CI 0.19–0.83); Other
(aOR=0.41, 95% CI 0.19–0.89)] and having ≥6 sexual partners
(aOR=2.29 95% CI 1.26–4.17) remained significantly associat-
ed with PrEP uptake. Transactional sex in past month was3
marginally associated with PrEP uptake (aOR=2.23, 95% CI
0.95–5.20) (Table 2).4. Discussion and conclusions
Our study shows that uptake of PrEP was low (21%) among high
risk individuals enrolled in an HIV vaccine preparedness study.
This finding confirms literature which shows that adoption of
PrEP in the real-world setting has been slow.[16] Demonstration
projects among well-defined at-risk populations such as
serodiscordant couples[17,18] and men who have sex with men
(MSM),[19] have reported high PrEP uptake. However, in a
population-based demonstration project in Uganda and Kenya,
uptake of PrEP was low (27%)[20] and similar to that in our
study. Consistent with previous studies,[19,21] we found that
individuals who reported high-risk behaviour such as engaging in
transactional sex and having multiple partners were more likely
to take up PrEP than those who did not. This may be because such
individuals perceive themselves as being at high risk of HIV
infection. On the other hand, low perceived risk of HIV may
explain the observed low uptake of PrEP among individuals
whose reported primary occupation was not sex work. For
example, although female bar workers commonly engage in
transactional sex, they often do not perceive themselves to be at
Table 2
Logistic regression analysis of predictors of oral PrEP uptake.
Bivariate analysis Multi-variable analysis
Characteristic N PrEP uptake (%)
OR (95% CI) P-value aOR (95% CI) P-valueOverall 362 75 (21)
Gender
Male 186 25 (13) Ref Ref
Female 176 50 (28) 2.56 (1.50 to 4.36) .001 1.53 (0.76 to 3.09) .237
Age
24 181 42 (23) Ref Ref
25 to 34 142 25 (18) 0.71 (0.41 to 1.23) 0.65 (0.35 to 1.18)
≥35 39 8 (21) 0.85 (0.36 to 2.00) .464 1.34 (0.51 to 3.48) .227
Education
Primary school and below 241 46 (19) Ref
Secondary school and above 121 29 (24) 1.34 (0.79 to 2.26) .281
Marital status
Single 163 33 (20) Ref
Married/cohabiting/relationship 148 27 (18) 0.88 (0.50 to 1.55)
Divorced/separated/widowed 51 15 (29) 1.64 (0.80 to 3.35) .254
Residence
Fishing village 140 18 (13) Ref Ref
Nonfishing village 222 57 (26) 2.34 (1.31 to 4.18) .004 2.40 (1.14 to 5.08) .020
Religion
Christian 277 58 (21) Ref
Muslim/other 85 17 (20) 0.94 (0.52 to 1.73) .852
Occupation
Sex worker 69 29 (42) 3.89 (2.20 to 6.90) <.001
Subsistence fisheries worker 74 13 (18) 0.78 (0.40 to 1.51) .454
Salon/lodge/bar worker, market/street vendor 104 22 (21) 1.04 (0.59 to 1.82) .897 0.40 (0.19 to 0.83) .014
Other
∗
141 19 (13) 0.46 (0.26 to 0.81) .007 0.41 (0.19 to 0.89) .024
Used a condom at last sex
No 270 46 (17) Ref
Yes 92 29 (32) 2.24 (1.30 to 3.86) .004
Transactional sex in past month
No 103 8 (8) Ref Ref
Yes 259 67 (26) 4.14 (1.91 to 8.98) <.001 2.23 (0.95 to 5.20) .065
Has anonymous/casual sexual partners
No 26 1 (4) Ref
Yes 336 74 (22) 7.06 (0.94 to 52.98) .057
Sexual partner is older by ≥10 yr
No 195 28 (14) Ref
Yes 167 47 (28) 2.33 (1.38 to 3.94) .001
Number of sexual partners last 3 mo
1–5 245 32 (13) Ref Ref
≥6 117 43 (37) 3.87 (2.28 to 6.56) <.001 2.29 (1.26 to 4.17) .006
Diagnosed with/treated for a STI in the past 3 mo
No 219 40 (18) Ref
Yes 143 35 (24) 1.45 (0.87 to 2.42) .155
Awareness of PrEP at baseline
No 221 37 (17) Ref
Yes 141 38 (27) 1.83 (1.10 to 3.06) .020
aOR=adjusted odds ratio, CI= confidence interval, N=number, OR=odds ratio, PrEP=pre-exposure prophylaxis, Ref= reference, STI= sexually transmitted infection.
Bold indicate the level of significance of the P-value <.05
∗
Professional/technical worker, sales/service worker, office clerk, student, etc.
Kusemererwa et al. Medicine (2021) 100:44 Medicinerisk of acquiring HIV.[22] Studies have shown that self-perceived
low risk of HIV infection is a major factor in the low uptake of
PrEP.[23]
We found that residence was significantly associated with PrEP
uptake with individuals who lived in nonfishing communities
having higher odds of uptake. Compared to fishing communities,
nonfishing communities in Uganda generally have better access to
healthcare services.[24] Factors that impede access to healthcare in
fishing communities include their usually remote locations, poor
road infrastructure and the resulting high cost of travel to and4
from healthcare facilities.[25,26] These findings are consistent with
previous studies which have showed that residence in urban areas
is associated with increased uptake of PrEP.[27,28]
Pill burden was the most common reason for not starting PrEP.
Similar findings have been reported in studies among MSM[23]
and other high risk populations.[29–32] This has been attributed to
concerns about the pill size or other attributes, and the burden of
daily pill-taking.[33]
Stigma was also a common reason for not starting PrEP.
Stigma has been reported as a barrier to PrEP uptake in other
Kusemererwa et al. Medicine (2021) 100:44 www.md-journal.comstudies,[34–36] and has been attributed to concerns such as having
to take the same pill that is used to treat HIV-positive persons and
PrEP being largely provided at HIV treatment clinics. Studies
have shown that PrEP is considered ART not just in the personal
understanding of PrEP but also in expectations of how others
perceive its use, thus causing fear of HIV-related stigma and
discrimination.[37] This potential stigma has been reported
among MSM in Kenya[38,39] and women at high risk of HIV
infection in South Africa.[40,41]
Another common reason for not starting PrEP was the need for
more time to consult partners on whether to take up PrEP or not.
Studies have shown that individuals would want their partners to
know whether they were taking PrEP or not,[42] while some want
their partners to support them in decision making. A study in
Uganda and Kenya reported that it was easier for men to initiate
PrEP without discussing it first with their partners. However,
women needed to seek permission from their partners to avoid
suspicion that its use would lead to infidelity and mistrust.[43]
A strength of the current study is that participants were not
offered PrEP by the study staff but referred to local PrEP
providers that were independent of the research team. Hence
uptake of PrEP required initiative from the participants and may
reflect what might happen in the real-world outside demonstra-
tion and/or research projects in which PrEP is provided by project
staff. Also, the longitudinal design of the study made it possible to
collect information on referral and PrEP uptake and document
reasons for nonuptake. Detailed qualitative research to under-
stand the facilitators and barriers to PrEP uptake in this
population is ongoing and will be reported separately. A major
limitation of this study is that PrEP uptake was self-reported. We
did not contact PrEP providers to verify the self-reports. Hence it
is possible that some participants may have falsely reported that
they had started PrEP. However, the fact that referrals were
provided only to participants who expressed interest to start PrEP
may have minimised this bias.
Uptake of PrEP in this cohort was low but associated with
reported indicators for high HIV risk behaviour and area of
residence. This points to the need for strategies that will help
individuals to properly evaluate their risk for them to make
informed decisions on whether to start PrEP or not. There is need
to improve access to PrEP services particularly in communities
with at risk populations and to devise strategies for reducing
stigma associated with PrEP use.Acknowledgments
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